[
  {
    "ts": null,
    "headline": "Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study",
    "summary": "Upstream Bio, Inc.'s Verekitug shows phase 2 success in CRSwNP; unique dosing, pipeline catalysts, and solid cash position suggest a Buy. Click for this UPB update.",
    "url": "https://finnhub.io/api/news?id=9b11013d87f9b17b375fce03b4a1811a1e9480559be782a8fea91e13c4e2c0c8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764953335,
      "headline": "Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study",
      "id": 137712661,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2248065607/image_2248065607.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Upstream Bio, Inc.'s Verekitug shows phase 2 success in CRSwNP; unique dosing, pipeline catalysts, and solid cash position suggest a Buy. Click for this UPB update.",
      "url": "https://finnhub.io/api/news?id=9b11013d87f9b17b375fce03b4a1811a1e9480559be782a8fea91e13c4e2c0c8"
    }
  },
  {
    "ts": null,
    "headline": "Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?",
    "summary": "Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=ee47f4d2a755d0c599cae1b6b50ff1d5e4981fa5b51fc4d9b4bc4320f8d307bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764952222,
      "headline": "Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?",
      "id": 137715886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=ee47f4d2a755d0c599cae1b6b50ff1d5e4981fa5b51fc4d9b4bc4320f8d307bb"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $750.11 as of December 1st. REGN’s trailing and forward P/E were 18.70 and 18.52 respectively according to Yahoo Finance. Regeneron Pharmaceuticals (REGN) […]",
    "url": "https://finnhub.io/api/news?id=c6b93ac906fb3efb1c31257f5b743bcb414ad92dea6365d2dcb628f714af3c4a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764901561,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory",
      "id": 137692826,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Notes From The Beauty Contest’s Substack by Crashkolnikov. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.’s share was trading at $750.11 as of December 1st. REGN’s trailing and forward P/E were 18.70 and 18.52 respectively according to Yahoo Finance. Regeneron Pharmaceuticals (REGN) […]",
      "url": "https://finnhub.io/api/news?id=c6b93ac906fb3efb1c31257f5b743bcb414ad92dea6365d2dcb628f714af3c4a"
    }
  }
]